Ozempic is a weekly injectable medication that causes significant weight loss, even though it’s technically approved by the FDA only for type 2 diabetes. In clinical trials, the active ingredient, semaglutide, produced an average weight loss of about 15% of body weight over 68 weeks. That’s roughly 35 to 40 pounds for someone starting at 250. The drug works by mimicking a natural gut hormone that controls appetite, slows digestion, and changes how your brain responds to food.
How Ozempic Causes Weight Loss
Semaglutide copies a hormone your body already makes called GLP-1. Normally, GLP-1 is released after you eat to help regulate blood sugar. It triggers insulin release, slows the movement of food through your stomach, and sends signals to your brain that you’re full. Ozempic does all of this, but at a much stronger and longer-lasting level than your natural hormone.
What makes semaglutide particularly effective for weight loss is what it does in the brain. It activates receptors in the hypothalamus, the brainstem, and the brain’s reward pathways, all regions that govern hunger, fullness, and the pleasure you get from eating. One especially interesting effect: it appears to increase feelings of fullness before you even start a meal, through what researchers describe as a “feed-forward” mechanism of cognitive satiation. In practical terms, people on Ozempic report thinking about food less, feeling satisfied sooner during meals, and losing interest in snacking or overeating.
What the Clinical Trials Show
The most widely cited evidence comes from the STEP 1 trial, where participants without diabetes who took 2.4 mg of semaglutide weekly (combined with lifestyle changes) lost an average of 14.9% of their body weight over 68 weeks. For context, the placebo group in the same trial, which also received lifestyle coaching, lost only about 2.4%. That gap is unusually large for a weight loss medication.
It’s worth noting that the 2.4 mg dose used in that trial is the dose found in Wegovy, the version of semaglutide that is FDA-approved specifically for weight loss. Ozempic maxes out at 2 mg per week and is approved only for type 2 diabetes and related cardiovascular and kidney risks. Many doctors prescribe Ozempic off-label for weight loss, partly because it has been easier to access or get covered by insurance in some cases. The active drug is identical in both products.
How the Dosing Works
Ozempic is injected once a week using a prefilled pen, typically in the stomach, thigh, or upper arm. The dose ramps up gradually to minimize side effects. You start at 0.25 mg weekly for the first four weeks, then increase to 0.5 mg. From there, your doctor may raise it to 1 mg or eventually 2 mg depending on your response and tolerance. Each step usually lasts at least four weeks before the next increase.
Most people don’t notice dramatic appetite changes at the lowest starting dose. The 0.25 mg phase is primarily about letting your body adjust. Weight loss tends to become more noticeable once you reach the 0.5 mg or 1 mg level, and it continues for months. Peak results in the clinical trials came around the 60- to 68-week mark.
Side Effects and What to Expect
Digestive side effects are extremely common, especially early on. In a two-year study, 82.2% of patients taking semaglutide experienced gastrointestinal symptoms, compared to 53.9% on placebo. The most frequent issues are nausea, diarrhea, constipation, bloating, stomach pain, and vomiting. These are rated as mild to moderate in most cases, and they tend to ease significantly after about 20 weeks of use as your body adjusts to the medication.
The gradual dose increase helps, but many people still deal with nausea during the first few months. Eating smaller meals, avoiding greasy or heavy foods, and staying hydrated can make a noticeable difference. If side effects are severe, your doctor may slow the dose escalation or hold at a lower dose longer.
Ozempic also carries a boxed warning, the FDA’s most serious label alert, related to thyroid tumors. In animal studies, semaglutide caused thyroid tumors in rodents. It’s not confirmed whether this applies to humans, but the drug is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2.
The Muscle Loss Problem
One of the more concerning findings about semaglutide weight loss involves how much of that weight comes from muscle rather than fat. In the STEP 1 trial, participants lost an average of 15.3 kg total, but 6.92 kg of that was lean mass. That means roughly 45% of the weight lost was muscle and other non-fat tissue, not just stored body fat.
This ratio is significantly worse than what’s typically expected. The general rule of thumb in weight loss research, sometimes called the “quarter fat-free mass rule,” predicts that about 25% of weight lost comes from lean tissue. Ozempic nearly doubles that proportion. For older adults or anyone already at risk for muscle loss, this is a meaningful concern. Resistance training and adequate protein intake during treatment are widely recommended to help preserve muscle, though research on how well these strategies offset the problem is still limited.
What Happens When You Stop
Weight regain after stopping semaglutide is the norm, not the exception. A large systematic review published in The BMJ found that people regain weight at an average rate of about 0.8 kg (roughly 1.75 pounds) per month after stopping newer, more potent versions of these drugs. That projects to nearly 10 kg (about 22 pounds) regained within the first year. At that pace, most people return to their original weight within approximately 1.5 years of stopping treatment.
This doesn’t mean the drug “failed.” It means obesity, for most people, is a chronic condition that responds to ongoing treatment, similar to how blood pressure medication controls hypertension but doesn’t cure it. Many doctors now frame semaglutide as a long-term or indefinite medication for this reason. If you’re considering starting, it helps to go in understanding that maintaining results will likely require staying on the drug or transitioning to another strategy.
Cardiovascular Benefits
Beyond weight loss, semaglutide has shown meaningful heart benefits. The SELECT trial found a 20% reduction in major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular death, among patients with obesity and established heart disease who did not have diabetes. This was a landmark finding because it demonstrated cardiovascular benefit from a weight loss drug independent of blood sugar control, and it’s one of the reasons semaglutide has reshaped how doctors think about treating obesity.
Cost Without Insurance
Ozempic is expensive. The list price is over $1,000 per pen. For patients paying out of pocket, the manufacturer offers a self-pay price of $199 per month for the first two months (at the lower starting doses), after which the standard cost rises to $349 per month for doses up to 1 mg and $499 per month for the 2 mg dose. Insurance coverage varies widely. Many plans cover Ozempic for type 2 diabetes but not for weight loss alone, which is part of why some patients and providers navigate the off-label prescribing route carefully.